A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

New England Journal of Medicine

Volumn 345, Issue 15, 2001, Pages 1091-1097

  Sargent, Daniel J ^a   Goldberg, Richard M ^a   Jacobson, Stacy D ^a   Macdonald, John S ^b   Labianca, Roberto ^c   Haller, Daniel G ^d   Shepherd, Lois E ^e   Seitz, Jean François ^f   Francini, Guido ^g  

^a MAYO CLINIC   (United States)

^b ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^c OSPEDALI RIUNITI   (Italy)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e QUEEN S UNIVERSITY   (Canada)

^f AIX MARSEILLE UNIVERSITY   (France)

^g UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; INCIDENCE; LEUKOPENIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; LEVAMISOLE; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0035846320     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa010957     Document Type: Article

References (58)

1. Population projections for states by age, sex, race, and Hispanic origin: 1995 to 2025
2. Risk and screening for colorectal cancer
3. Cancer in the elderly: Why so badly treated?
4. A national population-based study of incidence of colorectal cancer and age: Implications for screening in older Americans
5. The National Cancer Data Base: Report on colon cancer
6. Representation of older patients in cancer treatment trials
7. Underrepresentation of patients 65 years of age or older in cancer-treatment trials
8. Cancer treatment protocols: Who gets chosen?
9. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies
10. Determinants of cancer therapy in elderly patients
11. Choice of cancer therapy varies with age of patient
12. Patterns of care related to age of breast cancer patients
13. Relationship between age at diagnosis and treatments received by cancer patients
14. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil
15. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
16. NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer
17. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
18. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer
19. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
20. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
21. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
22. Stage III colon cancers: Why adjuvant chemotherapy is not offered to elderly patients
23. Population based variation in the use of chemotherapy for colorectal cancer in the elderly
24. Epidemiology and aging
25. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer
26. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial
27. Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome
28. Statistical aspects of the analysis of data from retrospective studies of disease
29. Regression models and life-tables
30. Proportional hazards tests and diagnostics based on weighted residuals
31. Nonparametric estimation from incomplete observations
32. Aging and pharmacology
33. Cancer chemotherapy in the elderly
34. Effect of age on therapeutic response and survival in advanced Hodgkin's disease
35. Pharmacology and organ toxicity of chemotherapy in older patients
36. Acute leukemia in the elderly
37. Cancer chemotherapy in the older patient: What the medical oncologist needs to know
38. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
39. Chemotherapy of metastatic breast cancer in the elderly: The Piedmont Oncology Association experience
40. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older
41. Adjuvant chemotherapy for colorectal cancer in the elderly: Population-based experience
42. Age and sex are independent predictors of 5-fluorouracil toxicity: Analysis of a large scale phase III trial
43. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number
44. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid
45. Advanced colorectal cancer in the elderly: Results of consecutive trials with 5-fluorouracil-based chemotherapy
46. Adjuvant treatment of colorectal cancer in the elderly
47. Clinical trials and drug toxicity in the elderly: The experience of the Eastern Cooperative Oncology Group
48. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse
49. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: Results in 28 patients including 13 patients receiving multimodality therapy
50. Cancer chemotherapy in the older patient
51. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer
52. Antimetabolites
53. Influence of sex and age on fluorouracil clearance
54. Dose-response effect of adjuvant chemotherapy in breast cancer
55. Dose: A critical factor in cancer chemotherapy
56. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance